Marathon Asset Management Ltd Has $16.63 Million Stock Position in Envista Holdings Corporation (NYSE:NVST)

Marathon Asset Management Ltd reduced its position in shares of Envista Holdings Corporation (NYSE:NVST - Free Report) by 9.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 963,584 shares of the company's stock after selling 102,719 shares during the period. Marathon Asset Management Ltd owned approximately 0.56% of Envista worth $16,632,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in shares of Envista by 1,338.3% during the first quarter. GAMMA Investing LLC now owns 33,139 shares of the company's stock worth $572,000 after buying an additional 30,835 shares in the last quarter. Two Sigma Advisers LP increased its holdings in shares of Envista by 66.6% during the fourth quarter. Two Sigma Advisers LP now owns 47,800 shares of the company's stock worth $922,000 after buying an additional 19,100 shares in the last quarter. Comerica Bank increased its holdings in shares of Envista by 8.2% during the fourth quarter. Comerica Bank now owns 121,851 shares of the company's stock worth $2,350,000 after buying an additional 9,248 shares in the last quarter. Norges Bank acquired a new position in shares of Envista during the fourth quarter worth $38,052,000. Finally, Natixis Advisors LLC increased its holdings in shares of Envista by 1.8% during the fourth quarter. Natixis Advisors LLC now owns 106,652 shares of the company's stock worth $2,057,000 after buying an additional 1,845 shares in the last quarter.

Envista Stock Performance

NYSE NVST opened at $19.69 on Friday. The company has a market capitalization of $3.34 billion, a price-to-earnings ratio of -3.01, a PEG ratio of 1.25 and a beta of 0.99. Envista Holdings Corporation has a twelve month low of $14.22 and a twelve month high of $23.00. The stock has a fifty day simple moving average of $17.80 and a 200 day simple moving average of $18.45. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.43.

Envista (NYSE:NVST - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.04. Envista had a positive return on equity of 4.07% and a negative net margin of 44.90%. The firm had revenue of $616.90 million during the quarter, compared to the consensus estimate of $608.17 million. During the same period last year, the business posted $0.26 EPS. The business's revenue was down 1.1% compared to the same quarter last year. Sell-side analysts expect that Envista Holdings Corporation will post 1 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Bank of America lowered their price target on shares of Envista from $26.00 to $23.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Baird R W upgraded shares of Envista from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 27th. Wells Fargo & Company set a $19.00 price target on shares of Envista in a report on Saturday, March 8th. Morgan Stanley set a $16.00 price target on shares of Envista in a report on Tuesday, April 15th. Finally, Needham & Company LLC restated a "hold" rating on shares of Envista in a report on Thursday, March 6th. One analyst has rated the stock with a sell rating, nine have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Envista currently has a consensus rating of "Hold" and a consensus target price of $20.23.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.